129 related articles for article (PubMed ID: 14767032)
1. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.
Kunin M; Kopolovic J; Avigdor A; Holtzman EJ
Nephrol Dial Transplant; 2004 Mar; 19(3):723-6. PubMed ID: 14767032
[No Abstract] [Full Text] [Related]
2. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
3. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
4. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Nagahama M; Sica DA
Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
[TBL] [Abstract][Full Text] [Related]
6. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
Desikan R; Veksler Y; Raza S; Stokes B; Sabir T; Li ZJ; Jagannath S
Br J Haematol; 2002 Nov; 119(2):496-9. PubMed ID: 12406092
[TBL] [Abstract][Full Text] [Related]
7. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells.
Dijkman HB; Weening JJ; Smeets B; Verrijp KC; van Kuppevelt TH; Assmann KK; Steenbergen EJ; Wetzels JF
Kidney Int; 2006 Jul; 70(2):338-44. PubMed ID: 16761013
[TBL] [Abstract][Full Text] [Related]
8. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
[No Abstract] [Full Text] [Related]
9. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome after treatment with pamidronate.
Markowitz GS; Fine PL; D'agati VD
Am J Kidney Dis; 2002 May; 39(5):1118-22. PubMed ID: 11979358
[No Abstract] [Full Text] [Related]
11. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
12. Collapsing glomerulopathy following anthracycline therapy.
Mohamed N; Goldstein J; Schiff J; John R
Am J Kidney Dis; 2013 May; 61(5):778-81. PubMed ID: 23219112
[TBL] [Abstract][Full Text] [Related]
13. Collapsing glomerulopathy.
Schwimmer JA; Markowitz GS; Valeri A; Appel GB
Semin Nephrol; 2003 Mar; 23(2):209-18. PubMed ID: 12704581
[TBL] [Abstract][Full Text] [Related]
14. Long-term pamidronate in multiple myeloma.
Seymour JF
J Clin Oncol; 1998 Jul; 16(7):2572-3. PubMed ID: 9667282
[No Abstract] [Full Text] [Related]
15. Pamidronate for early-stage, untreated myeloma.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
J Clin Oncol; 2003 Aug; 21(16):3177-8; author reply 3178. PubMed ID: 12915612
[No Abstract] [Full Text] [Related]
16. Myeloma--the therapeutic challenge.
Berenson JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():19-21. PubMed ID: 11089383
[TBL] [Abstract][Full Text] [Related]
17. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma presenting as collapsing glomerulopathy.
Bhowmik D; Dinda AK; Gupta S; Agarwal SK; Tiwari SC; Dash SC
Indian J Pathol Microbiol; 2003 Apr; 46(2):233-4. PubMed ID: 15022922
[TBL] [Abstract][Full Text] [Related]
20. Collapsing glomerulopathy: expanding interest in a shrinking tuft.
Meyrier AY
Am J Kidney Dis; 1999 Apr; 33(4):801-3. PubMed ID: 10196029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
